Your browser doesn't support javascript.
loading
Exploring factors related to clinically advanced fibrosis in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.
Yu, Anthony; Ritenour, Alexandra; Vincent, Jennifer; Park, Chanhyun; Rascati, Karen; Godley, Paul.
Afiliação
  • Yu A; Department of Pharmacy, Baylor Scott & White Health, Temple, USA.
  • Ritenour A; Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, USA.
  • Vincent J; Department of Pharmacy, Baylor Scott & White Health, Temple, USA.
  • Park C; Division of Gastroenterology, Baylor Scott & White Health, Temple, USA.
  • Rascati K; Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, USA.
  • Godley P; Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, USA.
Postgrad Med ; 136(1): 14-21, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38032542
ABSTRACT

OBJECTIVES:

To describe the clinical profile of nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) patients in a Texas integrated delivery network (IDN) and elucidate the local relationship between patient factors and the risk of advanced fibrosis.

METHODS:

This observational, retrospective, cross-sectional study utilized existing data from the electronic health record at a large Texas IDN. Data was collected during the study period from 1 January 2019, to 1 March 2023. Patient characteristics, comorbidities, labs, and medication orders were collected from the most recent encounter in which a Fibrosis-4 (FIB-4) score could be calculated. Chi square tests and analysis of variance (ANOVA) tests were conducted to evaluate differences among the three fibrosis risk categories. Ordinal logistic regression was utilized to assess associations between select variables and a higher risk of advanced fibrosis.

RESULTS:

A total of 56,253 patients were included in the study. 34,839 (61.9%) were Low-Risk 15,578 (27.7%) were Intermediate-Risk, and 5,836 (10.4%) were High-Risk of advanced fibrosis. Results showed that up to 70.4% of patients within a risk group were obese. Only 49.5% of patients in the High-Risk group had at least one gastroenterologist or hepatologist visit. Males, Medicare patients, former smokers, and those with hypertension, type 2 diabetes, and chronic kidney disease were associated with a higher risk of advanced fibrosis.

CONCLUSION:

This study highlights the need for early screening and proactive management of metabolic risk factors for patients with NAFLD/NASH. The findings indicate a notable prevalence of obesity in the study population, a need for specialist referral for those at High-Risk of advanced fibrosis, and the importance of routine labs to evaluate metabolic factors. Primary care providers may be ideal providers to target these interventions and address this care need.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Hepatopatia Gordurosa não Alcoólica Limite: Aged / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Hepatopatia Gordurosa não Alcoólica Limite: Aged / Humans / Male País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article